The FDA has released updated information about post-marketing reports of bleeding associated with dabigatran. They found the risk of bleeding does NOT appear to be higher than warfarin; similar to the results of randomized controlled trials. They will continue to monitor this and other anticoagulants, but for now there does not appear to by any reason to prohibit prescribing, if done for FDA approved indications (Afib), at doses appropriate for creatine clearance (FDA site)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.